Karyopharm Extends Creditor Forbearance Again, Now to November 1, 2026
KPTI sits 71% above its 52-week low of $0.31 on elevated volume (3.7× avg).
Summary
Karyopharm extended its creditor forbearance period from October 22 to November 1, 2026 — its second short extension in two weeks, with no new financing or restructuring terms disclosed.
Key Events · Legal and Risk Events · KPTI
-
Forbearance Extended to November 1
Under Section 19 of the Forbearance Agreement dated September 10, 2026, the applicable parties extended the end of the Forbearance Period from 11:59 p.m. Eastern on October 22, 2026 to 11:59 p.m. Eastern on November 1, 2026.
-
Second Extension in Two Weeks
This follows the October 14, 2026 8-K that pushed the same deadline from October 15 to October 22, 2026 — a pattern of short rolling extensions rather than a resolution.
-
No New Money or Terms Disclosed
The filing contains no new financing, no amended debt terms and no cash infusion; the September 11, 2026 8-K disclosed a missed $15.8M debt payment and warned the company may not survive.
-
Ten-Day Window to Reach a Deal
The company now has until November 1, 2026 to reach an agreement with creditors or face expiration of the standstill.
Analysis · KPTI · Life Sciences
The standstill with noteholders remains in place, but Karyopharm has now pushed the deadline twice in two weeks — first to October 22, now to November 1. That buys only ten more days, and the filing discloses no new financing, no debt restructuring terms and no cash infusion. The underlying problem is unchanged: the company previously disclosed substantial doubt about its ability to continue as a going concern and a cash runway that ended in September 2026. Each short extension keeps the company alive, yet it also keeps creditors in control of the timetable; a missed payment or a lapse of forbearance would let noteholders act on the default.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.3% of the 1526 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KPTI was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4M. The 52-week trading range was $0.31 to $10.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.